Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant Therapy With Trastuzumab and Chemotherapy and the Resultant Pathologic Complete Response Observed in HER2 Positive Breast Cancer;a Systematic Review

NCT05931042 is registered in ClinicalTrials.gov with Rawalpindi Medical College as lead sponsor.

NCT NCT05931042
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05931042 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant Therapy With Trastuzumab and Chemotherapy and the Resultant Pathologic Complete Response Observed in HER2 Positive Breast Cancer;a Systematic Review
Lead sponsor
Rawalpindi Medical College
Phase
Observational
Overall status
Completed
Start date
June 1, 2023
Completion date
June 18, 2023
Enrollment
1,209 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

her2+ breast cancer